BlackRock Group’s Immune Design Corp. IMDZ Stock Holding History

BlackRock Group’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$94K	Buy	17,129 +14,416	+531%	+$102K	﹤0.01%	2839
2016 Q3	$20K	Hold	2,713	–	–	﹤0.01%	2975
2016 Q2	$22K	Hold	2,713	–	–	﹤0.01%	2992
2016 Q1	$36K	Sell	2,713 -3,324	-55%	-$38.4K	﹤0.01%	2984
2015 Q4	$122K	Hold	6,037	–	–	﹤0.01%	2632
2015 Q3	$74K	Sell	6,037 -6,878	-53%	-$129K	﹤0.01%	2772
2015 Q2	$267K	Buy	12,915 +10,694	+481%	+$253K	﹤0.01%	2494
2015 Q1	$47K	Buy	+2,221	New	+$58K	﹤0.01%	2780

Other funds holding IMDZ

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock Group's IMDZ Position: Q4 2016 in Review

BlackRock Group increased its Immune Design Corp. (IMDZ) stake by 531% in Q4 2016, buying an estimated $102K and bringing the position to 17,129 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #2839.

BlackRock Group first reported a position in IMDZ in Q1 2015 and has held it in 8 quarters since. The position peaked at $267K in Q2 2015. 65 funds tracked by Wall St. Rank hold IMDZ as of Q4 2016.

BlackRock Group held 17,129 shares of Immune Design Corp. worth $94K as of Q4 2016.
BlackRock Group bought 14,416 Immune Design Corp. shares in Q4 2016, an estimated $102K.
Immune Design Corp. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2839 holding.
BlackRock Group first reported a position in Immune Design Corp. in Q1 2015 and has held it in 8 quarters since.
BlackRock Group's Immune Design Corp. position peaked at $267K in Q2 2015.
65 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.